The tumor microenvironment in hepatocellular carcinoma (Review)

International Journal of Oncology

Volumn 40, Issue 6, 2012, Pages 1733-1747

  Leonardi, Giulia Costanza ^a   Candido, Saverio ^a   Cervello, Melchiorre ^b   Nicolosi, Daria ^a   Raiti, Fabio ^a   Travali, Salvatore ^a   Spandidos, Demetrios A ^c   Libra, Massimo ^a  

^a UNIVERSITY OF CATANIA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF CRETE   (Greece)

Author keywords

Cytokines; Hepatitis; Hepatocellular carcinoma; Liver; Matrix metalloproteinases; Tumor microenvironment; Virus infections

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BRIVANIB; CETUXIMAB; EOTAXIN 2; ERLOTINIB; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 8; LINIFANIB; MACROPHAGE DERIVED CHEMOKINE; NITRIC OXIDE; PROGRAMMED DEATH 1 LIGAND 1; RAMUCIRUMAB; SORAFENIB; STROMAL CELL DERIVED FACTOR 1; STROMELYSIN; SUNITINIB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN A;

CD4+ CD25+ T LYMPHOCYTE; CELL DEATH; CELL HYPOXIA; CELL MIGRATION; CELL PROLIFERATION; CRYOGLOBULINEMIA; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIUM CELL; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; KUPFFER CELL; LARGE CELL LYMPHOMA; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN PROCESSING; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; STELLATE CELL; TH17 CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANIMALS; AVIAN PROTEINS; CARCINOMA, HEPATOCELLULAR; CYTOKINES; EXTRACELLULAR MATRIX; HEPATITIS, VIRAL, HUMAN; HUMANS; LIVER NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84861782272     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1408     Document Type: Review

References (285)

1. Mbeunkui F and Johann DJ: Cancer and the tumor microenvironment: a review of an essential relationship. Cancer Chemother Pharmacol 63: 571-582, 2009.
2. Witz IP and Levy-Nissenbaum O: The tumor microenvironment in the post-PAGET era. Cancer Lett 242: 1-10, 2006. (Pubitemid 44485302)
3. Balkwill F and Mantovani A: Inflammation and cancer: back to virchow? Lancet 357: 539-545, 2001. (Pubitemid 32173595)
4. Finch CE and Crimmins EM: Inflammatory exposure and historical changes in human life-spans. Science 305: 1736-1739, 2004. (Pubitemid 39249633)
5. Mantovani A, Allavena P, Sica A and Balkwill F. Cancer-related inflammation. Nature 454: 436-444, 2008.
6. Balkwill F, Charles KA and Mantovani A: Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217, 2005. (Pubitemid 40568680)
7. Koehne CH and Dubois RN: COX-2 inhibition and colorectal cancer. Semin Oncol 31: 12-21, 2004. (Pubitemid 38879410)
8. Flossmann E and Rothwell PM: Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 369: 1603-1613, 2007. (Pubitemid 46710123)
9. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
10. Bruix J, Boix L, Sala M and Llovet JM: Focus on hepatocellular carcinoma. Cancer Cell 5: 215-219, 2004. (Pubitemid 38402113)
11. Amann T, Bataille F, Spruss T, Muhlbauer M, Gabele E, Scholmerich J, Kiefer P, Bosserhoff AK and Hellerbrand C: Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 100: 646-653, 2009.
12. Mohla S and Witz IP: The 5th International Conference on Tumor Microenvironment: Progression, Therapy and Prevention Versailles, France, October 20-24, 2009: conference summary. Cancer Microenviron 3: 1-5, 2010.
13. De Wever O, Demetter P, Mareel M and Bracke M: Stromal myo-fibroblasts are drivers of invasive cancer growth. Int J Cancer 123: 2229-2238, 2008.
14. Xing F, Saidou J and Watabe K: Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 15: 166-179, 2010.
15. Anzola M: Hepatocellular carcinoma: role of hepatitis B and hepatitis C viruses proteins in hepatocarcinogenesis. J Viral Hepat 11: 383-393, 2004.
16. Donato F, Boffetta P and Puoti M: A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 75: 347-354, 1998. (Pubitemid 28100034)
17. Brechot C, Jaffredo F, Lagorce D, Gerken G, Meyer zum Buschenfelde K, Papakonstontinou A, Hadziyannis S, Romeo R, Colombo M, Rodes J, Bruix J, Williams R and Naoumov N: Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action. J Hepatol 29: 173-183, 1998. (Pubitemid 28352801)
18. Di Bisceglie AM: Hepatitis C. Lancet 351: 351-355, 1998.
19. Zhang JY, Dai M, Wang X, Lu WQ, Li DS, Zhang MX, Wang KJ, Dai LP, Han SG, Zhou YF and Zhuang H: A case-control study of hepatitis B and C virus infection as risk factors for hepatocellular carcinoma in Henan, China. Int J Epidemiol 27: 574-578, 1998. (Pubitemid 28431497)
20. Sun CA, Farzadegan H, You SL, Lu SN, Wu MH, Wolfe L, Hardy W, Huang GT, Yang PM, Lee H and Chen CJ: Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infections in hepatocellular carcinogenesis: a population-based case-control study in Taiwan. Cancer Epidemiol Biomarkers Prev 5: 173-178, 1996.
21. Tsai JF, Jeng JE, Ho MS, Chang WY, Hsieh MY, Lin ZY and Tsai JH: Effect of hepatitis C and B virus infection on risk of hepatocellular carcinoma: a prospective study. Br J Cancer 76: 968-974, 2003.
22. Grivennikov SI, Greten FR and Karin M: Immunity, inflammation, and cancer. Cell 140: 883-899, 2010.
23. Rapicetta M, Ferrari C and Levrero M: Viral determinants and host immune responses in the pathogenesis of HBV infection. J Med Virol 67: 454-457, 2002.
24. Rehermann B: Intrahepatic T cells in hepatitis B: viral control versus liver cell injury. J Exp Med 191: 1263-1268, 2000.
25. Guidotti LG, Rochford R, Chung J, Shapiro M, Purcell R and Chisari FV: Viral clearance without destruction of infected cells during acute HBV infection. Science 284: 825-829, 1999. (Pubitemid 29291352)
26. Kakimi K, Lane TE, Wieland S, Asensio VC, Campbell IL, Chisari FV and Guidotti LG: Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 194: 1755-1766, 2001. (Pubitemid 34028655)
27. Koike K: Hepatocarcinogenesis in hepatitis viral infection: lessons from transgenic mouse studies. J Gastroenterol 37: 55-64, 2002.
28. Freeman AJ, Marinos G, Ffrench RA and Lloyd AR: Immunopathogenesis of hepatitis C virus infection. Immunol Cell Biol 79: 515-536, 2001. (Pubitemid 33070441)
29. Nakamura I and Imawari M: Cellular immune response in HCV infection. J Gastroenterol 35: 881-889, 2000. (Pubitemid 32042381)
30. Krawczynski K, Alter MJ, Tankersley DL, Beach M, Robertson BH, Lambert S, Kuo G, Spelbring JE, Meeks E, Sinha S and Carson DA: Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 173: 822-828, 1996. (Pubitemid 26176003)
31. Gomez J, Martell M, Quer J, Cabot B and Esteban JI: Hepatitis C viral quasispecies. J Viral Hepat 6: 3-16, 1999. (Pubitemid 29077621)
32. Ngui SL, Hallet R and Teo CG: Natural and iatrogenic variation in hepatitis B virus. Rev Med Virol 9: 183-209, 1999. (Pubitemid 29410507)
33. Bertoletti A, Sette A, Chisari FV, Penna A, Levrero M, De Carli M, Fiaccadori F and Ferrari C: Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 369: 407-410, 1994. (Pubitemid 24184055)
34. Lanzavecchia A: Understanding the mechanisms of sustained signaling and T cell activation. J Exp Med 185: 1717-1719, 1997.
35. Sloan-Lancaster J, Evavold BD and Allen PM: Induction of T-cell anergy by altered T-cell-receptor ligand on live antigenpresenting cells. Nature 363: 156-159, 1993. (Pubitemid 23147012)
36. Nakamoto Y, Guidotti LG, Kuhlen CV, Fowler P and Chisari FV: Immune pathogenesis of hepatocellular carcinoma. J Exp Med 188: 341-350, 1998. (Pubitemid 28357762)
37. Karin M, Lawrence T and Nizet V: Innate immunity gone awry: linking microbial infections to chronic inflammation and cancer. Cell 124: 823-835, 2006. (Pubitemid 43261455)
38. Hussain SP, Hofseth LJ and Harris CC: Radical causes of cancer. Nat Rev Cancer 3: 276-285, 2003. (Pubitemid 37328863)
39. Hofseth LJ, Saito S, Hussain SP, Espey MG, Miranda KM, Araki Y, Jhappan C, Higashimoto Y, He P, Linke SP, Quezado MM, Zurer I, Rotter V, Wink DA, Appella E and Harris CC: Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci USA 100: 143-148, 2003. (Pubitemid 36078042)
40. Hagen TM, Huang S, Curnutte J, Fowler P, Martinez V, Wehr CM, Ames BN and Chisari FV: Extensive oxidative DNA damage in hepatocytes of transgenic mice with chronic active hepatitis destined to develop hepatocellular carcinoma. Proc Natl Acad Sci USA 91: 12808-12812, 1994.
41. Forgues M, Difilippantonio MJ, Linke SP, Ried T, Nagashima K, Feden J, Valerie K, Fukasawa K and Wang XW: Involvement of Crm1 in HBx-induced aberrant centriole replication and abnormal mitotic spindles. Mol Cell Biol 23: 5282-5292, 2003. (Pubitemid 36950883)
42. Kim YC, Song KS, Yoon G, Nam MJ and Ryu WS: Activated ras oncogene collaborates with HBx gene of hepatitis B virus to transform cells by suppressing HBx-mediated apoptosis. Oncogene 20: 16-23, 2001. (Pubitemid 32142334)
43. Yoshida T, Hanada T, Tokuhisa T, Kosai K, Sata M, Kohara M and Yoshimura A: Activation of STAT3 by the hepatitis C virus core protein leads to cellular transformation. J Exp Med 196: 641-653, 2002. (Pubitemid 35024442)
44. Wang W, Budhu A, Forgues M and Wang XW: Temporal and spatial control of nucleophosmin by the Ran-Crm1 complex in centrosome duplication. Nat Cell Biol 7: 823-830, 2005. (Pubitemid 41079055)
45. Large MK, Kittlesen DJ and Hahn YS: Suppression of host immune response by the core protein of hepatitis C virus: possible implications for hepatitis C virus persistence. J Immunol 162: 931-938, 1999. (Pubitemid 29035418)
46. You LR, Chen CM and Lee YHW: Hepatitis C virus core protein enhances NF-κB signal pathway triggering by lymphotoxinbeta receptor ligand and tumor necrosis factor alfa. J Virol 73: 1672-1681, 1999.
47. Lee CH, Choi YH, Yang SH, Lee CW, Ha SJ and Sung YC: Hepatitis C virus core protein inhibits interleukin 12 and nitric oxide production from activated macrophages. Virology 279: 271-279, 2001. (Pubitemid 34161017)
48. Wu CG, Budhu A, Chen S, Zhou X, Popescu NC, Valerie K and Wang XW: Effect of hepatitis C virus core protein on the molecular profiling of human B lymphocyte. Mol Med 12: 47-53, 2006. (Pubitemid 44128377)
49. Chan-Fook C, Jiang WR, Clarke BE, Zitzmann N, Maidens C, McKeating JA and Jones IM: Hepatitis C virus glycoprotein E2 binding to CD81: the role of E1E2 cleavage and protein glycosylation in bioactivity. Virology 273: 60-66, 2000. (Pubitemid 30602008)
50. Reyes GR: The nonstructural NS5A protein of hepatitis C virus: an expanding, multifunctional role in enhancing hepatitis C virus pathogenesis. J Biomed Sci 9: 187-197, 2002.
51. Carretero M, Gomez-Gonzalo M, Lara-Pezzi E, Benedicto I, Aramburu J, Martinez-Martinez S, Redondo J and Lopez- Cabrera M: The hepatitis B virus X protein binds to and activates the NH(2)-terminal trans-activation domain of nuclear factor of activated T cells-1. Virology 299: 288-300, 2002.
52. Libra M, De Re V, De Vita S, Gasparotto D, Gloghini A, Rupolo M, Degan M, Marzotto A, Stivala F, Carbone A and Boiocchi M: Low frequency of bcl-2 rearrangement in HCV-associated non-Hodgkin's lymphoma tissue. Leukemia 17: 1433-1436, 2003. (Pubitemid 36857363)
53. Libra M, De Re V, Gloghini A, Gasparotto D, Gragnani L, Navolanic PM, De Vita S, Mazzarino MC, Zignego AL, Carbone A and Boiocchi M: Detection of bcl-2 rearrangement in mucosaassociated lymphoid tissue lymphomas from patients with hepatitis C virus infection. Haematologica 89: 873-874, 2004. (Pubitemid 38981354)
54. Libra M, Indelicato M, De Re V, Zignego AL, Chiocchetti A, Malaponte G, Dianzani U, Nicoletti F, Stivala F, McCubrey JA and Mazzarino MC: Elevated serum levels of osteopontin in HCV-associated lymphoproliferative disorders. Cancer Biol Ther 4: 1192-1194, 2005.
55. Libra M, Capello D, Gloghini A, Laura P, Berra E, Cerri M, Gasparotto D, Franca S, De Re V, Gaidano G and Carbone A: Analysis of aberrant somatic hypermutation (SHM) in non-Hodgkin's lymphomas of patients with chronic HCV infection. J Pathol 206: 87-91, 2005. (Pubitemid 40613438)
56. Libra M, Gloghini A, De Re V, Rupolo M, Navolanic PM, Gasparotto D, Stivala F, Spina M, Boiocchi M and Carbone A: Aggressive forms of non-Hodgkin's lymphoma in two patients bearing coinfection of Epstein-Barr and hepatitis C viruses. Int J Oncol 26: 945-950, 2005.
57. Libra M, Mangano K, Anzaldi M, Quattrocchi C, Donia M, Di Marco R, Signorelli S, Scalia G, Zignego AL, De Re V, Mazzarino MC and Nicoletti F: Analysis of interleukin (IL)-1beta IL-1 receptor antagonist, soluble IL-1 receptor type II and IL-1 accessory protein in HCV-associated lymphoproliferative disorders. Oncol Rep 15: 1305-1308, 2006.
58. Libra M, Gloghini A, Malaponte G, Gangemi P, De Re V, Cacopardo B, Spandidos DA, Nicoletti F, Stivala F, Zignego AL and Carbone A: Association of t(14;18) translocation with HCV infection in gastrointestinal MALT lymphomas. J Hepatol 49: 170-174, 2008.
59. De Re V, Caggiari L, De Vita S, Mazzaro C, Lenzi M, Galli M, Monti G, Ferri C, Zignego AL, Gabrielli A, Sansonno D, Dammacco F, Libra M, Sacchi N, Talamini R, Spina M, Cannizzaro R, Guidoboni M and Dolcetti R: Genetic insights into the disease mechanisms of type II mixed cryoglobulinemia induced by hepatitis C virus. Dig Liver Dis 39: 65-71, 2007.
60. De Re V, Caggiari L, Simula MP, De Vita S, Mazzaro C, Lenzi M, Massimo GM, Monti G, Ferri C, Zignego AL, Gabrielli A, Sansonno D, Dammacco F, Libra M, Sacchi N, Talamini R, Spina M, Tirelli U, Cannizzaro R and Dolcetti R: Role of the HLA class II: HCV-related disorders. Ann NY Acad Sci 1107: 308-318, 2007. (Pubitemid 47528808)
61. De Re V, Caggiari L, Monti G, Libra M, Spina M, Dolcetti R, De Zorzi M, Racanelli V, Crovatto M and Toffoli G: HLA DR-DQ combination associated with the increased risk of developing human HCV positive non-Hodgkin's lymphoma is related to the type II mixed cryoglobulinemia. Tissue Antigens 75: 127-135, 2010.
62. Libra M, Polesel J, Russo AE, De Re V, Cinà D, Serraino D, Nicoletti F, Spandidos DA, Stivala F and Talamini R: Extrahepatic disorders of HCV infection: a distinct entity of B-cell neoplasia? Int J Oncol 36: 1331-1340, 2010.
63. Kalluri R and Zeisberg M: Fibroblasts in cancer. Nat Rev Cancer 6: 392-401, 2006.
64. Ostman A and Augsten M: Cancer-associated fibroblasts and tumor growth-bystanders turning into key players. Curr Opin Genet Dev 19: 67-73, 2009.
65. Pietras K and Ostman A: Hallmarks of cancer: interactions with the tumor stroma. Exp Cell Res 316: 1324-1331, 2010.
66. Bhowmick NA, Neilson EG and Moses HL: Stromal fibroblasts in cancer initiation and progression. Nature 432: 332-337, 2004. (Pubitemid 39551661)
67. Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005. (Pubitemid 40692295)
68. Infante JR, Matsubayashi H, Sato N, Tonascia J, Klein AP, Riall TA, Yeo C, Iacobuzio-Donahue C and Goggins M: Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 25: 319-325, 2007. (Pubitemid 350003021)
69. Mueller L, Goumas FA, Affeldt M, et al: Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am J Pathol 171: 1608-1618, 2007. (Pubitemid 350158321)
70. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K and Sahai E: Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 9: 1392-1400, 2007. (Pubitemid 350201752)
71. Fransvea E, Mazzocca A, Antonaci S and Giannelli G: Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatology 49: 839-850, 2009.
72. Friedman SL, Roll FJ, Boyles J and Bissell DM: Hepatic lipocytes: the principal collagen-producing cells of normal rat liver. Proc Natl Acad Sci USA 82: 8681-8685, 1985. (Pubitemid 16101107)
73. Wynn TA: Cellular and molecular mechanisms of fibrosis. J Pathol 214: 199-210, 2008.
74. Bataller R and Brenner DA: Liver fibrosis. J Clin Invest 115: 209-218, 2005. (Pubitemid 40385459)
75. Friedman SL: Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 88: 125-172, 2008.
76. Dubuisson L, Lepreux S, Bioulac-Sage P, Balabaud C, Costa AM, Rosenbaum J and Desmoulière A: Expression and cellular localization of fibrillin-1 in normal and pathological human liver. J Hepatol 34: 514-522, 2001. (Pubitemid 32328507)
77. Xia Y, Chen R, Song Z, Ye S, Sun R, Xue Q and Zhang Z: Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum. J Cancer Res Clin Oncol 136: 309-321, 2010.
78. Sancho-Bru P, Juez E, Moreno M, et al: Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. Liver Int 30: 31-41, 2010.
79. Eghbali-Fatourechi G, Sieck GC, Prakash YS, Maercklein P, Gores GJ and Fitzpatrick LA: Type I procollagen production and cell proliferation is mediated by transforming growth factor-beta in a model of hepatic fibrosis. Endocrinology 137: 1894-1903, 1996. (Pubitemid 26133966)
80. Campbell JS, Hughes SD, Gilbertson DG, et al: Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 102: 3389-3394, 2005. (Pubitemid 40328055)
81. Roderfeld M, Weiskirchen R, Wagner S, Berres ML, Henkel C, Grötzinger J, Gressner AM, Matern S and Roeb E: Inhibition of hepatic fibrogenesis by matrix metalloproteinase-9 mutants in mice. FASEB J 20: 444-454, 2006. (Pubitemid 44933321)
82. Schulze-Krebs A, Preimel D, Popov Y, Bartenschlager R, Lohmann V, Pinzani M and Schuppan D: Hepatitis C virusreplicating hepatocytes induce fibrogenic activation of hepatic stellate cells. Gastroenterology 129: 246-258, 2005. (Pubitemid 41002058)
83. Martín-Vílchez S, Sanz-Cameno P, Rodríguez- Muñoz Y, Majano PL, Molina-Jiménez F, López-Cabrera M, Moreno- Otero R and Lara-Pezzi E: The hepatitis B virus X protein induces paracrine activation of human hepatic stellate cells. Hepatology 47: 1872-1883, 2008. (Pubitemid 351945555)
84. Nitta T, Kim JS, Mohuczy D and Behrns KE: Murine cirrhosis induces hepatocyte epithelial mesenchymal transition and alterations in survival signaling pathways. Hepatology 48: 909-919, 2008.
85. Kluwe J, Pradere JP, Gwak GY, Mencin A, De Minicis S, Osterreicher CH, Colmenero J, Bataller R and Schwabe RF: Modulation of hepatic fibrosis by c-Jun-N-terminal kinase inhibition. Gastroenterology 138: 347-359, 2010.
86. Moles A, Tarrats N, Fernandez-Checa JC and Mari M: Cathepsins B and D drive hepatic stellate cell proliferation and promote their fibrogenic potential. Hepatology 49: 1297-1307, 2009.
87. Sokolovic A, Sokolovic M, Boers W, Elferink RP and Bosma PJ: Insulin-like growth factor binding protein 5 enhances survival of LX2 human hepatic stellate cells. Fibrogenesis Tissue Repair 3: 3, 2010.
88. Mantovani A, Bottazzi B, Colotta F, Sozzani S and Ruco L: The origin and function of tumor-associated macrophages. Immunol Today 13: 265-270, 1992.
89. Bunt SK, Yang L, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67: 10019-10026, 2007. (Pubitemid 47621253)
90. Coussens LM, Tinkle CL, Hanahan D and Werb Z: MMP-9 supplied by bone marrow derived cells contributes to skin carcinogenesis. Cell 103: 481-490, 2000.
91. Mantovani A, Sozzani S, Locati M, Allavena P and Sica A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555, 2002. (Pubitemid 35223554)
92. Mantovani A, Sica A, Allavena P, Garlanda C and Locati M: Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 70: 325-330, 2009.
93. Biswas SK and Mantovani A: Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 11: 889-896, 2010.
94. Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174, 2009.
95. Movahedi K, Laoui D, Gysemans C, Baeten M, Stangè G, van den Bossche J, Mack M, Pipeleers D, In't Veld P, De Baetselier P and van Ginderachter JA: Different tumor microenvironments contain functionally distinct subsets of macrophages derived from Ly6C (high) monocytes. Cancer Res 70: 5728-5739, 2010.
96. Barajas M, Mazzolini G, Genove G, Bilbao R, Narvaiza I, Schmitz V, Sangro B, Melero I, Qian C and Prieto J: Gene therapy of orthotopic hepatocellular carcinoma in rats using adenovirus coding for interleukin 12. Hepatology 33: 52-61, 2001. (Pubitemid 32016887)
97. Wu K, Kryczek I, Chen L, Zou W and Welling TH: Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer Res 69: 8067-8075, 2009.
98. Ramaiah SK and Rittling S: Pathophysiological role of osteopontin in hepatic inflammation, toxicity, and cancer. Toxicol Sci 103: 4-13, 2008. (Pubitemid 351524472)
99. Castellano G, Malaponte G, Mazzarino MC, Figini M, Marchese F, Gangemi P, Travali S, Stivala F, Canevari S and Libra M: Activation of the osteopontin/matrix metalloproteinase-9 pathway correlates with prostate cancer progression. Clin Cancer Res 14: 7470-7480, 2008.
100. Bui JD and Schreiber RD: Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes? Curr Opin Immunol 19: 203-208, 2007. (Pubitemid 46356963)
101. + regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198: 1875-1886, 2003.
102. Fu J, Xu D, Liu Z, et al: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132: 2328-2339, 2007. (Pubitemid 46890865)
103. Gao Q, Qiu SJ, Fan J, Zhou J, Wang XY, Xiao YS, Xu Y, Li YW and Tang ZY: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J Clin Oncol 25: 2586-2593, 2007. (Pubitemid 47041232)
104. Shen X, Li N, Li H, Zhang T, Wang F and Li Q: Increased prevalence of regulatory T cells in the tumor microenvironment and its correlation with TNM stage of hepatocellular carcinoma. J Cancer Res Clin Oncol 136: 1745-1754, 2010.
105. Kryczek I, Banerjee M, Cheng P, Vatan L, Szeliga W, Wei S, Huang E, Finlayson E, Simeone D, Welling TH, Chang A, Coukos G, Liu R and Zou W: Phenotype, distribution, generation, and functional and clinical relevance of Th17 cells in the human tumor environments. Blood 114: 1141-1149, 2009.
106. Bronte V: Th17 and cancer: friends or foes? Blood 112: 214, 2008.
107. Murugaiyan G and Saha B: Protumor vs antitumor functions of IL-17. J Immunol 183: 4169-4175, 2009.
108. Zhang JP, Yan J, Xu J, Pang XH, Chen MS, Li L, Wu C, Li SP and Zheng L: Increased intratumoral IL-17-producing cells correlate with poor survival in hepatocellular carcinoma patients. J Hepatol 50: 980-989, 2009.
109. Ryschich E, Lizdenis P, Ittrich C, et al: Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 66: 198-211, 2006. (Pubitemid 43166026)
110. Amin DN, Hida K, Bielenberg DR and Klagsbrun M: Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 66: 2173-2180, 2006.
111. Rolny C, Nilsson I, Magnusson P, et al: Platelet-derived growth factor receptor beta promotes early endothelial cell differentiation. Blood 108: 1877-1886, 2006. (Pubitemid 44394997)
112. Yu Q: The dynamic roles of angiopoietins in tumor angiogenesis. Future Oncol 1: 475-484, 2005.
113. Benetti A, Berenzi A, Gambarotti M, Garrafa E, Gelati M, Dessy E, Portolani N, Piardi T, Giulini SM, Caruso A, Invernici G, Parati EA, Nicosia R and Alessandri G: Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res 68: 8626-8634, 2008.
114. Xiong YQ, Sun HC, Zhang W, et al: Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells. Clin Cancer Res 15: 4838-4846, 2009.
115. Pietras K, Pahler J, Bergers G and Hanahan D: Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 5: e19, 2008.
116. Zhu XD, Zhang JB, Zhuang PY, Zhu HG, Zhang W, Xiong YQ, Wu WZ, Wang L, Tang ZY and Sun HC: High expression of macrophage colony stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 26: 2707-2716, 2008.
117. Farren MR, Carlson LM and Lee KP: Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunol Res 46: 165-176, 2010.
118. Li L, Li SP, Min J and Zheng L: Hepatoma cells inhibit the differentiation and maturation of dendritic cells and increase the production of regulatory T cells. Immunol Lett 114: 38-45, 2007. (Pubitemid 47625596)
119. Takai H, Kato A, Kato C, Watanabe T, Matsubara K, Suzuki M and Kataoka H: The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Liver Int 29: 1056-1064, 2009.
120. Ogasawara S, Yano H, Iemura A, Hisaka T and Kojiro M: Expressions of basic fibroblast growth factor and its receptors and their relationship to proliferation of human hepatocellular carcinoma cell lines. Hepatology 24: 198-205, 1996. (Pubitemid 26249434)
121. Neaud V, Faouzi S, Guirouilh J, Le Bail B, Balabaud C, Bioulac-Sage P and Rosenbaum J: Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 26: 1458-1466, 1997. (Pubitemid 27520010)
122. Uchimura K, Morimoto-Tomita M, Bistrup A, Li J, Lyon M, Gallagher J, Werb Z and Rosen SD: HSulf-2, an extracellular endoglucosamine-6-sulfatase, selectively mobilizes heparinbound growth factors and chemokines: effects on VEGF, FGF-1, and SDF-1. BMC Biochem 7: 2, 2006.
123. Wang S, Ai X, Freeman SD, Pownall ME, Lu Q, Kessler DS and Emerson CP Jr: QSulf1, a heparan sulfate 6-O-endosulfatase, inhibits fibroblast growth factor signalling in mesoderm induction and angiogenesis. Proc Natl Acad Sci USA 101: 4833-4838, 2004. (Pubitemid 38469163)
124. Lai JP, Chien JR, Moser DR, et al: hSulf1 sulfatase promotes apoptosis of hepatocellular cancer cells by decreasing heparinbinding growth factor signaling. Gastroenterology 126: 231-248, 2004. (Pubitemid 38040739)
125. Lai JP, Sandhu DS, Yu C, et al: Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology 47: 1211-1222, 2008. (Pubitemid 351547907)
126. Hossain MM, Hosono-Fukao T, Tang R, Sugaya N, van Kuppevelt TH, Jenniskens GJ, Kimata K, Rosen SD and Uchimura K: Direct detection of HSulf-1 and HSulf-2 activities on extracellular heparan sulfate and their inhibition by PI-88. Glycobiology 20: 175-186, 2010.
127. Liu CJ, Lee PH, Lin DY, et al: Heparanase inhibitor PI-88 as adjuvant therapy for hepatocellular carcinoma after curative resection: a randomized phase II trial for safety and optimal dosage. J Hepatol 50: 958-968, 2009.
128. Faouzi S, Le Bail B, Neaud V, Boussarie L, Saric J, Bioulac-Sage P, Balabaud C and Rosenbaum J: Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J Hepatol 30: 275-284, 1999. (Pubitemid 29071192)
129. Ooi LP, Crawford DH, Gotley DC, et al: Evidence that 'myo-fibroblast- like' cells are the cellular source of capsular collagen in hepatocellular carcinoma. J Hepatol 26: 798-807, 1997. (Pubitemid 27145702)
130. Ji J, Zhao L, Budhu A, Forgues M, Jia HL, Qin LX, Ye QH, Yu J, Shi X, Tang ZY and Wang XW: Let-7g targets collagen type I alpha2 and inhibits cell migration in hepatocellular carcinoma. J Hepatol 52: 690-697, 2010.
131. Miner JH: Laminins and their roles in mammals. Microsc Res Tech 71: 349-356, 2008.
132. Giannelli G, Fransvea E, Bergamini C, Marinosci F and Antonaci S: Laminin-5 chains are expressed differentially in metastatic and nonmetastatic hepatocellular carcinoma. Clin Cancer Res 9: 3684-3691, 2003. (Pubitemid 37169236)
133. Giannelli G, Bergamini C, Fransvea E, Sgarra C and Antonaci S: Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 129: 1375-1383, 2005. (Pubitemid 41597379)
134. Silva R, D'Amico G, Hodivala-Dilke KM and Reynolds LE: Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 28: 1703-1713, 2008.
135. Fu Y, Fang Z, Liang Y, Zhu X, Prins P, Li Z, Wang L, Sun L, Jin J, Yang Y and Zha X: Overexpression of integrin beta 1 inhibits proliferation of hepatocellular carcinoma cell SMMC-7721 through preventing Skp2-dependent degradation of p27 via PI3K pathway. J Cell Biochem 102: 704-718, 2007. (Pubitemid 47557423)
136. Carter WG, Kaur P, Gil SG, Gahr PJ and Wayner EA: Distinct functions for integrins alpha 3 beta 1 in focal adhesions and alpha 6 beta 4/bullous pemphigoid antigen in a new stable anchoring contact (SAC) of keratinocytes: relation to hemidesmosomes. J Cell Biol 111: 3141-3154, 1990. (Pubitemid 120034049)
137. Giannelli G, Bergamini C, Fransvea E, Marinosci F, Quaranta V and Antonaci S: Human hepatocellular carcinoma (HCC) cells require both alpha3beta1 integrin and matrix metalloproteinases activity for migration and invasion. Lab Invest 81: 613-627, 2001. (Pubitemid 32298807)
138. Bergamini C, Sgarra C, Trerotoli P, Lupo L, Azzariti A, Antonaci S and Giannelli G: Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology 46: 1801-1809, 2007.
139. Mizuno H, Ogura M, Saito Y, et al: Changes in adhesive and migratory characteristics of hepatocellular carcinoma (HCC) cells induced by expression of alpha3beta1 integrin. Biochim Biophys Acta 1780: 564-570, 2008. (Pubitemid 351381248)
140. Cressman DE, Greenbaum LE, De Angelis RA, Ciliberto G, Furth EE, Poli V and Taub R: Liver failure and defective hepatocyte regeneration in interleukin-6-deficient mice. Science 274: 1379-1383, 1996. (Pubitemid 26391463)
141. Ohno H, Kaneko S, Lin Y, Kobayashi K and Murakami S: Human hepatitis B virus X protein augments the DNA binding of nuclear factor for IL-6 through its basic-leucine zipper domain. J Med Virol 58: 11-18, 1999. (Pubitemid 29172115)
142. Song IH, Binh VQ, Duy DN, Kun JF, Bock TC, Kremsner PG and Luty AJ: Serum cytokine profiles associated with clinical presentation in Vietnamese infected with hepatitis B virus. J Clin Virol 28: 93-103, 2003. (Pubitemid 36970109)
143. Lee Y, Park US, Choi I, Yoon SK, Park YM and Lee YI: Human interleukin 6 gene is activated by hepatitis B virus-X protein in human hepatoma cells. Clin Cancer Res 4: 1711-1717, 1998. (Pubitemid 28304733)
144. Nakagawa H, Maeda S, Yoshida H, et al: Serum IL-6 levels and the risk for hepatocarcinogenesis in chronic hepatitis C patients: an analysis based on gender differences. Int J Cancer 125: 2264-2269, 2009.
145. Tilg H, Wilmer A, Vogel W, Herold M, Nölchen B, Judmaier G and Huber C: Serum levels of cytokines in chronic liver diseases. Gastroenterology 103: 264-274, 1992.
146. Wong VW, Yu J, Cheng AS, Wong GL, Chan HY, Chu ES, Ng EK, Chan FK, Sung JJ and Chan HL: High serum interleukin-6 level predicts future hepatocellular carcinoma development in patients with chronic hepatitis B. Int J Cancer 124: 2766-2770, 2009.
147. Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 9: 798-809, 2009.
148. Littman DR and Rudensky AY: Th17 and regulatory T cells in mediating and restraining inflammation. Cell 140: 845-858, 2010.
149. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM and Karin M: Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science 317: 121-124, 2007. (Pubitemid 47056470)
150. Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H and Karin M: Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140: 197-208, 2010.
151. Reichner JS, Mulligan JA, Spisni R, Sotomayor EA, Albina JE and Bland KI: Effect of IL-6 overexpression on the metastatic potential of rat hepatocellular carcinoma cells. Ann Surg Oncol 5: 279-286, 1998. (Pubitemid 28249321)
152. Coskun U, Bukan N, Sancak B, Gunel N, Ozenirler S, Unal A and Yucel A: Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions. Neoplasma 51: 209-213, 2004. (Pubitemid 38821501)
153. Ben Ari Z, Mor E, Papo O, Kfir B, Sulkes J, Tambur AR, Tur-Kaspa R and Klein T: Cytokine gene polymorphisms in patients infected with hepatitis B virus. Am J Gastroenterol 98: 144-150, 2003. (Pubitemid 36135183)
154. Giannitrapani L, Soresi M, Giacalone A, Campagna ME, Marasà M, Cervello M, Marasà S and Montalto G: IL-6-174G/C polymorphism and IL-6 serum levels in patients with liver cirrhosis and hepatocellular carcinoma. OMICS 15: 183-186, 2011.
155. Park BL, Lee HS, Kim YJ, Kim JY, Jung JH, Kim LH and Shin HD: Association between interleukin 6 promoter variants and chronic hepatitis B progression. Exp Mol Med 35: 76-82, 2003. (Pubitemid 36626937)
156. Fausto N, Campbell JS and Riehle KJ: Liver regeneration. Hepatology 43: 45-53, 2006.
157. Karin M: Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436, 2006.
158. Wheelhouse NM, Chan YS, Gillies SE, Caldwell H, Ross JA, Harrison DJ and Prost S: TNF-alfa induced DNA damage in primary murine hepatocytes. Int J Mol Med 12: 889-894, 2003.
159. Shiraki K, Yamanaka T, Inoue H, Kawakita T, Enokimura N, Okano H, Sugimoto K, Murata K and Nakano T: Expression of TNF-related apoptosis-inducing ligand in human hepatocellular carcinoma. Int J Oncol 26: 1273-1281, 2005.
160. Huang YS, Hwang SJ, Chan CY, Wu JC, Chao Y, Chang FY and Lee SD: Serum levels of cytokines in hepatitis C-related liver disease: a longitudinal study. Zhonghua Yi Xue Za Zhi (Taipei) 62: 327-333, 1999. (Pubitemid 29289363)
161. Nakazaki H: Preoperative and postoperative cytokines in patients with cancer. Cancer 70: 709-713, 1992.
162. Kakumu S, Okumura A, Ishikawa T, Yano M, Enomoto A, Nishimura H, Yoshioka K and Yoshika Y: Serum levels of IL-10, IL-15 and soluble tumor necrosis factor-alfa (TNF-alfa) receptors in type C chronic liver disease. Clin Exp Immunol 109: 458-463, 1997. (Pubitemid 27402313)
163. Bortolami M, Venturi C, Giacomelli L, Scalerta R, Bacchetti S, Marino F, Floreani A, Lise M, Naccarato R and Farinati F: Cytokine, infiltrating macrophage and T cell-mediated response to development of primary and secondary human liver cancer. Dig Liver Dis 34: 794-801, 2002. (Pubitemid 36097519)
164. Zekri AR, Ashour MS, Hassan A, Alam El-Din HM, El Shehaby AM and Abu-Shady MA: Cytokine profile in Egyptian hepatitis C virus genotype-4 in relation to liver disease progression. World J Gastroenterol 11: 6624-6630, 2005. (Pubitemid 43072701)
165. Ho SY, Wang YJ, Chen HL, Chen CH, Chang CJ, Wang PJ, Chen HH and Guo HR: Increased risk of developing hepatocellular carcinoma associated with carriage of the TNF2 allele of the -308 tumor necrosis factor-β promoter gene. Cancer Causes Control 15: 657-663, 2004. (Pubitemid 39060927)
166. Heneghan MA, Johnson PJ, Clare M, Ho S, Harrison PM and Donaldson PT: Frequency and nature of cytokine gene polymorphisms in hepatocellular carcinoma in Hong Kong Chinese. Int J Gastrointest Cancer 34: 19-26, 2003. (Pubitemid 38962757)
167. Talaat RM, Esmail AA, Elwakil R, Gurgis AA and Nasr MI: Tumor necrosis factor-alpha -308G/A polymorphism and risk of hepatocellular carcinoma in hepatitis C virus-infected patients. Chin J Cancer 31: 29-35, 2012.
168. Akira S, Uematsu S and Takeuchi O: Pathogen recognition and innate immunity. Cell 124: 783-801, 2006. (Pubitemid 43261452)
169. Han YP, Zhou L, Wang J, Xiong S, Garner WL, French SW and Tsukamoto H: Essential role of matrix metalloproteinases in interleukin-1-induced myofibroblastic activation of hepatic stellate cell in collagen. J Biol Chem 279: 4820-4828, 2004. (Pubitemid 38199077)
170. Hirankarn N, Kimkong I, Kummee P, Tangkijvanich P and Poovorawan Y: Interleukin-1β gene polymorphism associated with hepatocellular carcinoma in hepatitis B virus infection. World J Gastroenterol 12: 776-779, 2006. (Pubitemid 43380763)
171. Tanaka Y, Furuta T, Suzuki S, Orito E, Yeo AE, Hirashima N, Sugauchi F, Ueda R and Mizokami M: Impact of interleukin-1βgenetic polymorphisms on the development of hepatitis C virusrelated hepatocellular carcinoma in Japan. J Infect Dis 187: 1822-1825, 2003. (Pubitemid 36667895)
172. Wang Y, Kato N, Hoshida Y, Yoshida H, Taniguchi H, Goto T, Moriyama M, Otsuka M, Shiina S, Shiratori Y, Ito Y and Omata M: Interleukin-1β gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection. Hepatology 37: 65-71, 2003. (Pubitemid 36042146)
173. Kitaoka S, Shiota G and Kawasaki H: Serum levels of interleukin-10, interleukin-12 and soluble interleukin-2 receptor in chronic liver disease type C. Hepatogastroenterology 50: 1569-1574, 2003. (Pubitemid 37186534)
174. Chia CS, Ban K, Ithnin H, Singh H, Krishnan R, Mokhtar S, Malihan N and Seow HF: Expression of interleukin-18, interferongamma and interleukin-10 in hepatocellular carcinoma. Immunol Lett 84: 163-172, 2002. (Pubitemid 35292375)
175. Beckebaum S, Zhang X, Chen X, Yu Z, Frilling A, Dworacki G, Grosse-Wilde H, Broelsch CE, Gerken G and Cicinnati VR: Increased levels of interleukin-10 in serum from patients with hepatocellular carcinoma correlate with profound numerical deficiencies and immature phenotype of circulating dendritic cell subsets. Clin Cancer Res 10: 7260-7269, 2004. (Pubitemid 39487713)
176. Chau GY, Wu CW, Lui WY, Chang TJ, Kao HL, Wu LH, King KL, Loong CC, Hsia CY and Chi CW: Serum interleukin-10 but not interleukin-6 is related to clinical outcome in patients with resectable hepatocellular carcinoma. Ann Surg 231: 552-558, 2000.
177. Shin HD, Park BL, Kim LH, Jung JH, Kim JY, Yoon JH, Kim YJ and Lee HS: Interleukin 10 haplotype associated with increased risk of hepatocellular carcinoma. Hum Mol Genet 12: 901-906, 2003. (Pubitemid 36504032)
178. Nieters A, Yuan JM, Sun CL, Zhang ZQ, Stoehlmacher J, Govindarajan S and Yu MC: Effect of cytokine genotypes on the hepatitis B virus-hepatocellular carcinoma association. Cancer 103: 740-748, 2005. (Pubitemid 40216402)
179. Migita K, Miyazoe S, Maeda Y, Daikoku M, Abiru S, Ueki T, Yano K, Nagaoka S, Matsumoto T, Nakao K, Hamasaki K, Yatsuhashi H, Ishibashi H and Eguchi K: Cytokine gene polymorphisms in Japanese patients with hepatitis B virus infection-association between TGF-β1 polymorphisms and hepatocellular carcinoma. J Hepatol 42: 505-510, 2005. (Pubitemid 40342929)
180. Budhu A, Forgues M, Ye QH, He P, Zanetti KA, Kammula US, Chen Y, Qin LX, Tang ZY and Wang XW: Prediction of venous metastases, recurrence and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell 10: 99-111, 2006. (Pubitemid 44202603)
181. Trinchieri G: Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol 3: 133-146, 2003.
182. Yamashita YI, Shimada M, Hasegawa H, et al: Electroporationmediated interleukin-12 gene therapy for hepatocellular carcinoma in the mice model. Cancer Res 61: 1005-1012, 2001. (Pubitemid 32174418)
183. Leonard JP, Sherman ML, Fisher GL, Buchanan LJ, Larsen G, Atkins MB, Sosman JA, Dutcher JP, Vogelzang NJ and Ryan JL: Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood 90: 2541-2548, 1997. (Pubitemid 27413462)
184. Sangro B, Mazzolini G, Ruiz J, et al: Phase I trial of intratumoral injection of an adenovirus encoding interleukin-12 for advanced digestive tumors. J Clin Oncol 22: 1389-1397, 2004. (Pubitemid 41103620)
185. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D and Yu H: IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 206: 1457-1464, 2009.
186. Gu FM, Li QL, Gao Q, Jiang JH, Zhu K, Huang XY, Pan JF, Yan J, Hu JH, Wang Z, Dai Z, Fan J and Zhou J: IL-17 induces AKT-dependent IL-6/JAK2/STAT3 activation and tumor progression in hepatocellular carcinoma. Mol Cancer 10: 150, 2011.
187. Massague J: TGFbeta in cancer. Cell 134: 215-230, 2008.
188. Yamazaki K, Masugi Y and Sakamoto M: Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-β signaling in hepatocarcinogenesis. Dig Dis 29: 284-288, 2011.
189. Bedossa P, Peltier E, Terris B, Franco D and Poynard T: Transforming growth factor-beta 1 (TGF-beta 1) and TGF-beta 1 receptors in normal, cirrhotic, and neoplastic human livers. Hepatology 21: 760-766, 1995.
190. Gomis RR, Alarcon C, Nadal C, van Poznak C and Massague J: C/EBPbeta at the core of the TGFbeta cytostatic response and its evasion in metastatic breast cancer cells. Cancer Cell 10: 203-214, 2006. (Pubitemid 44311064)
191. Murata T, Ohshima T, Yamaji M, Hosaka M, Miyanari Y, Hijikata M and Shimotohno K: Suppression of hepatitis C virus replicon by TGF-β. Virology 331: 407-417, 2005. (Pubitemid 40075466)
192. Matsuzaki K, Murata M, Yoshida K, et al: Chronic inflammation associated with hepatitis C virus infection perturbs hepatic transforming growth factor beta signaling, promoting cirrhosis and hepatocellular carcinoma. Hepatology 46: 48-57, 2007. (Pubitemid 47171920)
193. Murata M, Matsuzaki K, Yoshida K, et al: Hepatitis B virus X protein shifts human hepatic transforming growth factor (TGF)-beta signaling from tumor suppression to oncogenesis in early chronic hepatitis B. Hepatology 49: 1203-1217, 2009.
194. Sohn BH, Park IY, Lee JJ, et al: Functional switching of TGF-beta1 signalling in liver cancer via epigenetic modulation of a single CpG site in TTP promoter. Gastroenterology 138: 1898-1908, 2010.
195. Fransvea E, Angelotti U, Antonaci S and Giannelli G: Blocking transforming growth factor-beta up-regulates E-cadherin and reduces migration and invasion of hepatocellular carcinoma cells. Hepatology 47: 1557-1566, 2008. (Pubitemid 351702739)
196. Giannelli G, Fransvea E, Marinosci F, Bergamini C, Colucci S, Schiraldi O and Antonaci S: Transforming growth factor-beta1 triggers hepatocellular carcinoma invasiveness via alpha3beta1 integrin. Am J Pathol 161: 183-193, 2002. (Pubitemid 34760784)
197. Katabami K, Mizuno H, Sano R, Saito Y, Ogura M, Itoh S and Tsuji T: Transforming growth factor-beta1 upregulates transcription of alpha3 integrin gene in hepatocellular carcinoma cells via Ets-transcription factor-binding motif in the promoter region. Clin Exp Metastasis 22: 539-548, 2005. (Pubitemid 43234638)
198. Mazzocca A, Fransvea E, Lavezzari G, Antonaci S and Giannelli G: Inhibition of transforming growth factor beta receptor I kinase blocks hepatocellular carcinoma growth through neo-angiogenesis regulation. Hepatology 50: 1140-1151, 2009.
199. Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S and Giannelli G: Downregulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross talk and tumor progression in hepatocellular carcinoma. Hepatology 51: 523-534, 2010.
200. Peinado H, Quintanilla M and Cano A: Transforming growth factor beta-1 induces snail transcription factor in epithelial cell lines: mechanisms for epithelial mesenchymal transitions. J Biol Chem 278: 21113-21123, 2003. (Pubitemid 36806424)
201. Van Zijl F, Mair M, Csiszar A, Schneller D, Zulehner G, Huber H, Eferl R, Beug H, Dolznig H and Mikulits W: Hepatic tumorstroma crosstalk guides epithelial to mesenchymal transition at the tumor edge. Oncogene 28: 4022-4033, 2009.
202. Wang B, Hsu SH, Majumder S, Kutay H, Huang W, Jacob ST and Ghoshal K: TGFbeta mediated upregulation of hepatic miR-181b promotes hepatocarcinogenesis by targeting TIMP3. Oncogene 29: 1787-1797, 2010.
203. Huang S, He X, Ding J, Liang L, Zhao Y, Zhang Z, Yao X, Pan Z, Zhang P, Li J, Wan D and Gu J: Upregulation of miR-23a approximately 27a approximately 24 decreases transforming growth factor-beta-induced tumor-suppressive activities in human hepatocellular carcinoma cells. Int J Cancer 123: 972-978, 2008. (Pubitemid 352032429)
204. Okumoto K, Hattori E, Tamura K, Kiso S, Watanabe H, Saito K, Saito T, Togashi H and Kawata S: Possible contribution of circulating transforming growth factor-β1 to immunity and prognosis in unresectable hepatocellular carcinoma. Liver Int 24: 21-28, 2004. (Pubitemid 38351210)
205. Kim YJ, Lee HS, Im JP, Min BH, Kim HD, Jeong JB, Yoon JH, Kim CY, Kim MS, Kim JY, Jung JH, Kim LH, Park BL and Shin HD: Association of transforming growth factor-β1 gene polymorphisms with a hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection. Exp Mol Med 35: 196-202, 2003. (Pubitemid 36841640)
206. Kim YJ, Kim HY, Kim JS, Lee JH, Yoon JH, Kim CY, Park BL, Cheong HS, Bae JS, Kim S, Shin HD and Lee HS: Putative association of transforming growth factor-alpha polymorphisms with clearance of hepatitis B virus and occurrence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Viral Hepat 17: 518-526, 2010.
207. Xiang TX, Cheng N, Li XN and Wu XP: Association between transforming growth factor-β1 polymorphisms and hepatocellular cancer risk: a meta-analysis. Hepatol Res doi: 10.1111/j.1872-034X.2011.00958.x [Epub ahead of print] 2012.
208. Gurtner GC, Werner S, Barrandon Y and Longaker MT: Wound repair and regeneration. Nature 453: 314-321, 2008. (Pubitemid 351693137)
209. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R and Rusnati M: Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 16: 159-178, 2005. (Pubitemid 40616114)
210. Ho HK, Pok S, Streit S, Ruhe JE, Hart S, Lim KS, Loo HL, Aung MO, Lim SG and Ullrich A: Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 50: 118-127, 2009.
211. Amann T, Bataille F, Spruss T, et al: Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol 176: 1433-1442, 2010.
212. Boix L, Rosa JL, Ventura F, Castells A, Bruix J, Rodés J and Bartrons R: c-MET mRNA overexpression in human hepatocellular carcinoma. Hepatology 19: 88-91, 1994. (Pubitemid 24020476)
213. Kiss A, Wang NJ, Xie JP and Thorgeirsson SS: Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth factor/c-met, TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 3: 1059-1066, 1997. (Pubitemid 27319751)
214. Tavian D, De PG, Benetti A, Portolani N, Giulini SM and Barlati S: u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int J Cancer 87: 644-649, 2000. (Pubitemid 30620405)
215. Ueki T, Fujimoto J, Suzuki T, Yamamoto H and Okamoto E: Expression of hepatocyte growth factor and its receptor, the c-met proto-oncogene, in hepatocellular carcinoma. Hepatology 25: 619-623, 1997. (Pubitemid 27106443)
216. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM and Thorgeirsson SS: Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest 116: 1582-1595, 2006.
217. Hirschi KK and D'Amore PA: Control of angiogenesis by the pericyte: molecular mechanisms and significance. EXS 79: 419-428, 1997.
218. Semela D and Dufour JF: Angiogenesis and hepatocellular carcinoma. J Hepatol 41: 864-880, 2004. (Pubitemid 39434320)
219. Avila MA, Berasain C, Sangro B and Prieto J: New therapies for hepatocellular carcinoma. Oncogene 25: 3866-3884, 2006. (Pubitemid 43980482)
220. Bangoura G, Liu ZS, Qian Q, Jiang CQ, Yang GF and Jing S: Prognostic significance of HIF-2alpha/EPAS1 expression in hepatocellular carcinoma. World J Gastroenterol 13: 3176-3182, 2007. (Pubitemid 47064579)
221. Liu LP, Liang HF, Chen XP, Zhang WG, Yang SL, Xu T and Ren L: The role of NFkappaB in Hepatitis b virus X proteinmediated upregulation of VEGF and MMPs. Cancer Invest 28: 443-451, 2010.
222. Yang JC, Teng CF, Wu HC, Tsai HW, Chuang HC, Tsai TF, Hsu YH, Huang W, Wu LW and Su IJ: Enhanced expression of vascular endothelial growth factor-A in ground glass hepatocytes and its implication in hepatitis B virus hepatocarcinogenesis. Hepatology 49: 1962-1971, 2009.
223. Dhar DK, Naora H, Yamanoi A, Ono T, Kohno H and Otani H: Requisite role of VEGF receptors in angiogenesis of hepatocellular carcinoma: a comparison with angiopoietin/Tie pathway. Anticancer Res 22: 379-386, 2002. (Pubitemid 34475326)
224. Ng IO, Poon RT, Lee JM, Fan ST, Ng M and Tso WK: Microvessel density, vascular endothelial growth factor and its receptors Flt-1 and Flk-1/KDR in hepatocellular carcinoma. Am J Clin Pathol 116: 838-845, 2001. (Pubitemid 33108154)
225. Poon RT, Ho JW, Tong CS, Lau C, Ng IO and Fan ST: Prognostic significance of serum vascular endothelial growth factor and endostatin in patients with hepatocellular carcinoma. Br J Surg 91: 1354-1360, 2004. (Pubitemid 39331462)
226. Shimamura T, Saito S, Morita K, Kitamura T, Morimoto M, Kiba T, Numata K, Tanaka K and Sekihara H: Detection of vascular endothelial growth factor and its receptor expression in human hepatocellular carcinoma biopsy specimens. J Gastroenterol Hepatol 15: 640-646, 2000. (Pubitemid 30435715)
227. Lian Z, Liu J, Wu M, Wang HY, Arbuthnot P, Kew M and Feitelson MA: Hepatitis B x antigen up-regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis. Hepatology 45: 1390-1399, 2007. (Pubitemid 46918323)
228. Yamaguchi R, Yano H, Iemura A, Ogasawara S, Haramaki M and Kojiro M: Expression of vascular endothelial growth factor in human hepatocellular carcinoma. Hepatology 28: 68-77, 1998. (Pubitemid 28299987)
229. Poon RT, Lau C, Yu WC, Fan ST and Wong J: High serum levels of vascular endothelial growth factor predict poor response to transarterial chemoembolization in hepatocellular carcinoma: a prospective study. Oncol Rep 11: 1077-1084, 2004.
230. Chao Y, Li CP, Chau GY, Chen CP, King KL, Lui WY, Yen SH, Chang FY, Chan WK and Lee SD: Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepatocellular carcinoma after surgery. Ann Surg Oncol 10: 355-362, 2003. (Pubitemid 40486931)
231. Li XM, Tang ZY, Zhou G, Lui YK and Ye SL: Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 17: 13-17, 1998. (Pubitemid 28215959)
232. Zhou J, Tang ZY, Fan J, Wu ZQ, Li XM, Liu YK, Liu F, Sun HC and Ye SL: Expression of platelet-derived endothelial cell growth factor and vascular endothelial growth factor in hepatocellular carcinoma and portal vein tumor thrombus. J Cancer Res Clin Oncol 126: 57-61, 2000. (Pubitemid 30006353)
233. Parks WC, Wilson CL and Lopez-Boado YS: Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 4: 617-629, 2004. (Pubitemid 39025047)
234. Libra M, Scalisi A, Vella N, Clementi S, Sorio R, Stivala F, Spandidos DA and Mazzarino C: Uterine cervical carcinoma: role of matrix metalloproteinases (Review). Int J Oncol 34: 897-903, 2009.
235. Kessenbrock K, Plaks V and Werb Z: Matrix metalloproteinases: regulators of the tumor microenvironment. Cell 141: 52-67, 2010.
236. Bourboulia D and Stetler-Stevenson WG: Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 20: 161-168, 2010.
237. Ou DP, Tao YM, Tang FQ and Yang LY: The hepatitis B virus X protein promotes hepatocellular carcinoma metastasis by upregulation of matrix metalloproteinases. Int J Cancer 120: 1208-1214, 2007.
238. Yu FL, Liu HJ, Lee JW, Liao MH and Shih WL: Hepatitis B virus X protein promotes cell migration by inducing matrix metalloproteinase-3. J Hepatol 42: 520-527, 2005.
239. Lara-Pezzi E, Gómez-Gaviro MV, Gálvez BG, Mira E, Iñiguez MA, Fresno M, Martínez-A C, Arroyo AG and López-Cabrera M: The hepatitis B virus X protein promotes tumor cell invasion by inducing membrane-type matrix metalloproteinase-1 and cyclooxygenase-2 expression. J Clin Invest 110: 1831-1838, 2002. (Pubitemid 36076490)
240. Zhao XL, Sun T, Che N, Sun D, Zhao N, Dong XY, Gu Q, Yao Z and Sun BC: Promotion of hepatocellular carcinoma metastasis through matrix metalloproteinase activation by epithelial-mesenchymal transition regulator twist1. J Cell Mol Med 15: 691-700, 2011.
241. Yu Q and Stamenkovic I: Localization of matrix metalloproteinase 9 to the cell surface provides a mechanism for CD44-mediated tumor invasion. Genes Dev 13: 35-48, 1999. (Pubitemid 29045114)
242. Mitsiades N, Yu WH, Poulaki V, Tsokos M and Stamenkovic I: Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res 61: 577-581, 2001. (Pubitemid 32128617)
243. Lin WW and Karin M: A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117: 1175-1183, 2007.
244. Manicone AM and McGuire JK: Matrix metalloproteinases as modulators of inflammation. Semin Cell Dev Biol 19: 34-41, 2008. (Pubitemid 350235986)
245. Kohga K, Tatsumi T, Takehara T, Tsunematsu H, Shimizu S, Yamamoto M, Sasakawa A, Miyagi T and Hayashi N: Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. J Hepatol 52: 872-879, 2010.
246. Littlepage LE, Sternlicht MD, Rougier N, et al: Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 70: 2224-2234, 2010.
247. Cheng JC, Chou CH, Kuo ML and Hsieh CY: Radiationenhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 25: 7009-7018, 2006. (Pubitemid 44722069)
248. Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J and Zhang LJ: Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol Res 39: 177-186, 2009.
249. Takafuji V, Forgues M, Unsworth E, Goldsmith P and Wang XW: An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. Oncogene 26: 6361-6371, 2007. (Pubitemid 47494216)
250. Arii S, Mise M, Harada T, Furutani M, Ishigami S, Niwano M, Mizumoto M, Fukumoto M and Imamura M: Overexpression of matrix metalloproteinase 9 gene in hepatocellular carcinoma with invasive potential. Hepatology 24: 316-322, 1996. (Pubitemid 26260026)
251. Fernández CA, Yan L, Louis G, Yang J, Kutok JL and Moses MA: The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 11: 5390-5395, 2005. (Pubitemid 41060812)
252. Kubben FJ, Sier CF, Hawinkels LJ, et al: Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 43: 1869-1876, 2007. (Pubitemid 47238246)
253. Smith ER, Zurakowski D, Saad A, Scott RM and Moses MA: Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 14: 2378-2386, 2008. (Pubitemid 351551071)
254. Zhang H, Xu L, Xiao D, et al: Upregulation of neutrophil gelatinase-associated lipocalin in oesophageal squamous cell carcinoma: significant correlation with cell differentiation and tumour invasion. J Clin Pathol 60: 555-561, 2007. (Pubitemid 46867169)
255. Kim JR and Kim CH: Association of a high activity of matrix metalloproteinase-9 to low levels of tissue inhibitors of metalloproteinase-1 and -3 in human hepatitis B-viral hepatoma cells. Int J Biochem Cell Biol 36: 2293-2306, 2004. (Pubitemid 39094450)
256. Xia D, Yan LN, Xie JG, Tong Y, Yan ML, Wang XP, Zhang MM and Zhao LY: Overexpression of TIMP-1 mediated by recombinant adenovirus in hepatocellular carcinoma cells inhibits proliferation and invasion in vitro. Hepatobiliary Pancreat Dis Int 5: 409-415, 2006. (Pubitemid 44295197)
257. Qi JH, Ebrahem Q, Moore N, Murphy G, Claesson-Welsh L, Bond M, Baker A and Anand-Apte B: A novel function for tissue inhibitor of metalloproteinases-3 (TIMP3): inhibition of angiogenesis by blockage of VEGF binding to VEGF receptor-2. Nat Med 9: 407-415, 2003. (Pubitemid 36460074)
258. Zhang H, Wang YS, Han G and Shi Y: TIMP-3 gene transfection suppresses invasive and metastatic capacity of human hepatocarcinoma cell line HCC-7721. Hepatobiliary Pancreat Dis Int 6: 487-491, 2007. (Pubitemid 47521162)
259. Chen X, Cheung ST, So S, Fan ST, Barry C, Higgins J, Lai KM, Ji J, Dudoit S, Ng IO, van de Rijn M, Botstein D and Brown PO: Gene expression patterns in human liver cancers. Mol Biol Cell 13: 1929-1939, 2002. (Pubitemid 34651483)
260. Lee JS, Heo J, Libbrecht L, et al: A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 12: 410-416, 2006.
261. Wu XZ, Xie GR and Chen D: Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 22: 1178-1182, 2007.
262. Liu L, Zhu XD, Wang WQ, Shen Y, Qin Y, Ren ZG, Sun HC and Tang ZY: Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res 16: 2740-2750, 2010.
263. Hamaguchi T, Iizuka N, Tsunedomi R, Hamamoto Y, Miyamoto T, Iida M, Tokuhisa Y, Sakamoto K, Takashima M, Tamesa T and Oka M: Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol 33: 725-731, 2008.
264. Roberts LR and Gores GJ: Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25: 212-225, 2005. (Pubitemid 40781073)
265. Gollob JA, Wilhelm S, Carter C and Kelley SL: Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol 33: 392-406, 2006. (Pubitemid 44142735)
266. Leicht DT, Balan V, Kaplun A, Singh-Gupta V, Kaplun L, Dobson M and Tzivion G: Raf kinases: function, regulation and role in human cancer. Biochim Biophys Acta 1773: 1196-1212, 2007. (Pubitemid 47161035)
267. Yoshida T, Hisamoto T, Akiba J, et al: Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25: 6056-6066, 2006. (Pubitemid 44562404)
268. Schuierer MM, Bataille F, Weiss TS, Hellerbrand C and Bosserhoff AK: Raf kinase inhibitor protein is downregulated in hepatocellular carcinoma. Oncol Rep 16: 451-456, 2006.
269. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M, Steveling K, Reis H, Cicinnati VR, Schmid KW and Baba HA: Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48: 83-90, 2008. (Pubitemid 350191996)
270. McKillop IH, Schmidt CM, Cahill PA and Sitzmann JV: Altered expression of mitogen-activated protein kinases in a rat model of experimental hepatocellular carcinoma. Hepatology 26: 1484-1491, 1997. (Pubitemid 27520013)
271. Ito Y, Sasaki Y, Horimoto M, et al: Activation of mitogenactivated protein kinases/extracellular signal-regulated kinases in human hepatocellular carcinoma. Hepatology 27: 951-958, 1998. (Pubitemid 28160479)
272. Huynh H, Chow PK and Soo KC: AZD6244 and doxorubicin induce growth suppression and apoptosis in mouse models of hepatocellular carcinoma. Mol Cancer Ther 6: 2468-2476, 2007. (Pubitemid 47480412)
273. Hwang YH, Choi JY, Kim S, Chung ES, Kim T, Koh SS, Lee B, Bae SH, Kim J and Park YM: Over-expression of c-raf-1 protooncogene in liver cirrhosis and hepatocellular carcinoma. Hepatol Res 29: 113-121, 2004. (Pubitemid 38667508)
274. Feng DY, Zheng H, Tan Y and Cheng RX: Effect of phosphorylation of MAPK and Stat3 and expression of c-fos and c-jun proteins on hepatocarcinogenesis and their clinical significance. World J Gastroenterol 7: 33-36, 2001. (Pubitemid 32170895)
275. Alexia C, Fallot G, Lasfer M, Schweizer-Groyer G and Groyer A: An evaluation of the role of insulin-like growth factors (IGF) and of type-I IGF receptor signalling in hepatocarcinogenesis and in the resistance of hepatocarcinoma cells against drug-induced apoptosis. Biochem Pharmacol 68: 1003-1015, 2004. (Pubitemid 39094263)
276. Desbois-Mouthon C, Cadoret A, Blivet-van Eggelpoël MJ, Bertrand F, Cherqui G, Perret C and Capeau J: Insulin and IGF-1 stimulate the beta-catenin pathway through two signalling cascades involving GSK-3beta inhibition and Ras activation. Oncogene 20: 252-259, 2001. (Pubitemid 32150270)
277. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM and Tai MH: Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97: 1929-1940, 2003.
278. Villanueva A, Chiang DY, Newell P, et al: Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 135: 1972-1983, 2008.
279. De La CA, Romagnolo B, Billuart P, et al: Somatic mutations of the beta-catenin gene are frequent in mouse and human hepatocellular carcinomas. Proc Natl Acad Sci USA 95: 8847-8851, 1998. (Pubitemid 28350577)
280. Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24, 2003. (Pubitemid 36627817)
281. Hoshida Y, Nijman SM, Kobayashi M, et al: Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 69: 7385-7392, 2009.
282. Cheng AL, Kang YK, Chen Z, et al: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
283. Kaspar M, Zardi L and Neri D: Fibronectin as target for tumor therapy. Int J Cancer 118: 1331-1339, 2006.
284. Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, Krissansen GW and Sun X: Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 99: 2055-2061, 2008.
285. WeiXing C, Tiantian H, Qun N, Chaohui Y and Ping X: Inhibitory effect of hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells. Med Oncol 25: 88-92, 2008.